Accord enters Europe as Coherus stays quiet
Accord Healthcare has capitalised on its market-leading European Commission approval for Pelgraz (pegfilgrastim) by making “meaningful sales” of the biosimilar neutropenia treatment in Germany within two days of launching. A trade introduction of Pelgraz in the UK is also underway, a company spokesperson told Generics bulletin.
You may also be interested in...
Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.